Ipsen Stock Slides 3.8% as Barclays Downgrade Stirs Earnings Concerns

Ipsen shares are trading down 3.8% at €157.6 on Monday, as a major analyst downgrade from Barclays reignites worries about the company’s medium-term earnings trajectory.

Barclays shifted its rating from Equalweight to Underweight and trimmed its price target from EUR170 to EUR155, contending that Ipsen’s robust 2026 delivery increasingly looks like a cyclical peak rather than a durable growth platform.

The crux of Barclays’ concern centers on three compounding headwinds: the accelerating decline in Somatuline sales as generic competition strengthens, the possibility that a rival’s CAM2029 drug candidate could prove clinically superior to Somatuline by late 2026 or early 2027, and the substantial reinvestment burden Ipsen must bear ahead of later-dated pipeline launches — all of which the bank sees as creating meaningful downside risk to 2027–2029 earnings estimates.

This echoes an earlier Jefferies downgrade that had flagged CAM2029 competition as capable of eroding Somatuline long-term revenue estimates by more than 35%. Ipsen’s own H1 2026 earnings call had already acknowledged that generic competition for Somatuline would likely pressure sales in the second half of 2026 and into 2027, and that a new entrant in second-line oncology was beginning to weigh on Onivyde revenues.

The broader market backdrop offered little relief, with U.S. indices trading in negative territory — the S&P 500 off 0.4% and the Dow Jones down 0.8% — reflecting a cautious risk environment that tends to amplify selling pressure on stocks facing company-specific headwinds.

Ipsen’s 52-week range of €109.9–€174.0 illustrates how sharply the stock has recovered over the past year, a re-rating that now appears vulnerable given the deteriorating analyst consensus.

Taken together, the Barclays downgrade served as the immediate trigger, but it landed on top of a pre-existing layer of competitive and structural concerns that the market had been monitoring since the H1 results.

The combination of a freshly bearish institutional view, a price target sitting below current trading levels, and macro softness proved sufficient to push Ipsen to its session low of €156.6 during today’s trading.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.